News

The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.

An investigational new drug application for VIPER-101, a chimeric antigen receptor T-cell therapy, has been cleared by the FDA in T-cell lymphoma.

A dual primary end point of progression-free survival in the phase 3 CheckMate-8HW trial evaluating nivolumab and ipilimumab in metastatic colorectal cancer has been met.

Significant findings from a number of trials in the lung cancer space will make their way into case reports.

Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.

The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.

Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.

Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.

Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.

Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.

The FDA has granted 2 designations to cretostimogene grenadenorepvec, an oncolytic immunotherapy, for the treatment of a specific type of high-risk bladder cancer:

Prospective models show a drop in the cost of running sentinel lymph node assessments when artificial intelligence is used.

In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.

Adding ribociclib to endocrine therapy shows efficacy and tolerability for those with hormone receptor–positive, HER2-negative advanced breast cancer, even in older patients.

TAR-200, a novel targeted therapy, has been granted breakthrough therapy designation by the FDA in high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.

In the first 3 cleared monotherapy cohorts of the VISTA-101 trial, KVA12123 showed promising safety and pharmacokinetics with a sign of efficacy across patients with advanced solid tumors.

Jeremy Abramson, MD, discusses what the findings from the phase 3 TRANSFORM study of lisocabtagene maraleucel mean for patients with relapsed large B-cell lymphoma.

An experimental drug combination of inavolisib, palbociclib, and fulvestrant significantly improved progression-free survival in patients with HR-positive/HER2-negative PIK3CA-mutated breast cancer.

The FDA has granted priority review to the supplemental biologics application of mirvetuximab soravtansin-gynx for the treatment of patients with platinum-resistant ovarian cancer.

Results from a retrospective study found that patients with certain features were at a greater risk of recurrence of papillary thyroid cancer.

Summary: The FDA has accepted for priority review nivolumab and cisplatin-based chemotherapy as a first line of treatment in patients with inoperable or metastatic urothelial carcinoma.

CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.

Older patients with stage 4 cancer often prioritize quality of life over survival time, according to recent research findings presented at the 2023 American Society of Clinical Oncology Quality Care Symposium.

Recent findings identified that overall and cancer-specific mortality risks were lowered in patients who used antidepressants following a diagnosis with hepatocellular carcinoma compared with patients that did not.

Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer.

New treatments can come with high price tags, and a population-based, retrospective study revealed that fewer than 25% of patients with cancer have a documented conversation about the financial aspects of their treatment.

The FDA has granted accelerated approval to pirtobrutinib for the treatment of patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.